title: Non-Hodgkin's lymphoma in systemic lupus erythematosus.
abstract: BACKGROUND
  Recent evidence supports an association between systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL).
  
  
  OBJECTIVE
  To describe demographic factors, subtypes, and survival of patients with SLE who develop NHL.
  
  
  METHODS
  A multi-site cohort of 9547 subjects with definite SLE was assembled. Subjects at each centre were linked to regional tumour registries to determine cancer cases occurring after SLE diagnosis. For the NHL cases ascertained, descriptive statistics were calculated, and NHL subtype frequency and median survival time of patients determined.
  
  
  RESULTS
  42 cases of NHL occurred in the patients with SLE during the 76,948 patient-years of observation. The median age of patients at NHL diagnosis was 57 years. Thirty six (86%) of the 42 patients developing NHL were women, reflecting the female predominance of the cohort. In the patients, aggressive histological subtypes appeared to predominate, with the most commonly identified NHL subtype being diffuse large B cell (11 out of 21 cases for which histological subtype was available). Twenty two of the patients had died a median of 1.2 years after lymphoma diagnosis.
  
  
  CONCLUSIONS
  These data suggest aggressive disease in patients with SLE who develop NHL. Continuing work should provide further insight into the patterns of presentation, prognosis, and aetiology of NHL in SLE.
authors.affiliation: Division of Clinical Epidemiology Montreal General Hospital, Montreal, PQ, Canada. sasha.bernatsky@mail.mcgill.ca
authors.forename: S
authors.initials: S
authors.lastname: Bernatsky
authors.forename: R
authors.initials: R
authors.lastname: Ramsey-Goldman
authors.forename: R
authors.initials: R
authors.lastname: Rajan
authors.forename: J-F
authors.initials: JF
authors.lastname: Boivin
authors.forename: L
authors.initials: L
authors.lastname: Joseph
authors.forename: S
authors.initials: S
authors.lastname: Lachance
authors.forename: D
authors.initials: D
authors.lastname: Cournoyer
authors.forename: A
authors.initials: A
authors.lastname: Zoma
authors.forename: S
authors.initials: S
authors.lastname: Manzi
authors.forename: E
authors.initials: E
authors.lastname: Ginzler
authors.forename: M
authors.initials: M
authors.lastname: Urowitz
authors.forename: D
authors.initials: D
authors.lastname: Gladman
authors.forename: P R
authors.initials: PR
authors.lastname: Fortin
authors.forename: S
authors.initials: S
authors.lastname: Edworthy
authors.forename: S
authors.initials: S
authors.lastname: Barr
authors.forename: C
authors.initials: C
authors.lastname: Gordon
authors.forename: S-C
authors.initials: SC
authors.lastname: Bae
authors.forename: J
authors.initials: J
authors.lastname: Sibley
authors.forename: K
authors.initials: K
authors.lastname: Steinsson
authors.forename: O
authors.initials: O
authors.lastname: Nived
authors.forename: G
authors.initials: G
authors.lastname: Sturfelt
authors.forename: Y
authors.initials: Y
authors.lastname: St Pierre
authors.forename: A
authors.initials: A
authors.lastname: Clarke
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000453:epidemiology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000453:epidemiology / Q000209:etiology / Q000235:genetics; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012042:Registries; D016019:Survival Analysis